Literature DB >> 8344741

From adjuvant to neo-adjuvant chemotherapy in high-risk breast cancer: the experience of the Milan Cancer Institute. Steiner Award Lecture 1992.

G Bonadonna1.   

Abstract

Entities:  

Mesh：

Year:  1993        PMID： 8344741     DOI： 10.1002/ijc.2910550102

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


× No keyword cloud information.
  5 in total

1.  Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors.

Authors:  K Szepeshazi; A V Schally; G Halmos; B Szoke; K Groot; A Nagy
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Does induction chemotherapy with a mitoxantrone/vinorelbine regimen allow a breast-conservative treatment in patients with operable locoregional breast cancer? A French Northern Oncology Group trial in 105 patients. French Northern Oncology Group.

Authors:  A Adenis; L Vanlemmens; C Fournier; B Hecquet; J Bonneterre
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

3.  Analysis of Arg-Gly-Asp mimetics and soluble receptor of tumour necrosis factor as therapeutic modalities for concanavalin A induced hepatitis in mice.

Authors:  R Bruck; H Shirin; R Hershkoviz; O Lider; G Kenet; H Aeed; Z Matas; L Zaidel; Z Halpern
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

4.  Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma.

Authors:  G Fontanini; D Campani; M Roncella; D Cecchetti; S Calvo; A Toniolo; F Basolo
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

Review 5.  The use of synthetic analogues of Arg-Gly-Asp (RGD) and soluble receptor of tumor necrosis factor to prevent acute and chronic experimental liver injury.

Authors:  R Bruck; R Hershkoviz; O Lider; H Shirin; H Aeed; Z Halpern
Journal:  Yale J Biol Med       Date:  1997 Jul-Aug
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.